Novartis AG

Milestones as listed on novartis.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Leadership as listed on novartis.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Products and services as listed on novartis.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Sites as listed on novartis.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for Novartis AG: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 3 Oct 2026.

Clinical trials 323 in our ClinicalTrials.gov registers · 17 in the EU register

Showing 10 of 323, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 1 registry name

Drugs in these trials 120 compounds

EU trials register (CTIS) 17 authorised or ongoing · 1 in Ireland

• A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease2025-522227-99-00 · Phase III · Ongoing · site in Ireland
• A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors2024-518348-19-00 · Phase I · Authorised
• A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive2025-523555-66-00 · Phase III · Ongoing
• A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC2025-523276-23-00 · Phase I/II · Authorised
• A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)2025-522019-40-00 · Phase I/II · Authorised
• A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa2025-523259-72-00 · Phase III · Authorised
• A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer2025-524080-20-00 · Phase I · Authorised
• An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors2025-521911-38-00 · Phase I/II · Ongoing

Recent approvals

• VijoiceEMA · alpelisib · 15 Jul 2026
• ItvismaEMA · onasemnogene abeparvovec · 30 Jun 2026
• RhapsidoEMA · remibrutinib · 23 Apr 2026

NICE technology appraisals 99 of its medicines · 83 current

• Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosisNICE TA1175 · Optimised · 9 Jul 2026
• Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and overNICE TA1140 · Optimised · 17 Mar 2026
• Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal)NICE TA1132 · Terminated (no company submission) · 17 Feb 2026
• Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)NICE TA1102 · Terminated (no company submission) · 29 Oct 2025
• Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and overNICE TA1088 · Not recommended · 13 Aug 2025
• Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrenceNICE TA1086 · Recommended · 6 Aug 2025
• Relugolix–estradiol–norethisterone for treating symptoms of endometriosisNICE TA1057 · Recommended · 16 Apr 2025
• Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and overNICE TA1054 · Recommended · 15 Apr 2025

Appraisals of medicines whose first EU or US authorisation was held by this company, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (Novartis AG): founded 1996, headquarters Basel, website novartis.com. Wikidata Q507154 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.

How this is matched: register records are linked to this page by the organisation name they carry, here Novartis Pharmaceuticals; Novartis Gene Therapies; Novartis Pharma AG; Novartis Europharm Limited; Novartis Pharma GmbH; Novartis Ireland Limited and 5 more. Spot a wrong match? Tell us.

From the annual reports Novartis AG files with the US Securities and Exchange Commission (20-F, IFRS), in USD as reported. Latest financial year: to Dec 2025.

Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.

Companies registered in Ireland 3 active in the CRO register

From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Novartis AG as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.